BMY - Better Buy: Mirati Therapeutics vs. Amgen
Look out, cancer: There could be two new sheriffs in town. Not long ago, Amgen (NASDAQ: AMGN) presented early results from the first clinical trial with easy-to-swallow capsules that fight cancer in a way previously considered impossible. More recently, Mirati Therapeutics (NASDAQ: MRTX) set the Twitter-verse on fire with initial results (from a program similar to Amgen's) that appear competitive.
Shares of Amgen and Mirati could soar on the backs of their experimental cancer treatments, but that's about all they have in common. Let's stack these biotech stocks side by side to figure out which is the better buy right now.
Image source: Getty Images.